This article is more than 5 years old. Information may no longer be current.
DePuy Synthes to co-promote non-opioid, local analgesic with Pacira Pharmaceuticals
Click Here to Manage Email Alerts
DePuy Synthes Companies announced an exclusive agreement between DePuy Synthes Sales Inc. and Pacira Pharmaceuticals Inc. to co-promote Exparel, a long-lasting, non-opioid, local analgesic administered at the orthopedic surgical site, in the United States.
According to a company press release, the agreement allows DePuy Synthes to promote Exparel across its joint reconstruction, spine, sports medicine and trauma businesses to help with post-surgical patient pain. Not only will this agreement further enhance the company’s portfolio and reach in the OR, the release noted it will also help hospital customers improve clinical outcomes, reduce costs and enhance patient satisfaction. The co-promotion of Exparel is expected to begin in the first quarter of 2017, according to the release.
“There are millions of orthopedic procedures performed in the U.S. market today where we can improve patient care and the surgical experience by offering a long acting, intraoperatively delivered local anesthetic infiltration solution,” Juan-José Gonzalez, president of DePuy Synthes U.S., said in the release. “As part of our focused approach to help bring value at every point along the care pathway, we are thrilled to be able to further our offerings through partnering with Pacira and together provide a differentiated solution for our customers to help improve patient outcomes.”
Reference: